Share Twitter LinkedIn Facebook Email Peter O’Donnell, MD of @UChicagoMed explains biomarkers in patients with locally advanced metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose"escalation.
Enhertu DESTINY-Breast06 Phase III Study the Impact on HR-Positive, HER2-Low Metastatic Breast Cancer Revealed Breast 4 Mins Read
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read